The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMedicus Pharma (MDCX) has announced the successful validation of its Phase 2 clinical trial data for SkinJect, reporting a significant overall response rate (ORR) of 80%. Following the initial report, the company issued formal guidance to clarify the interpretation of the Phase 2 topline dataset. This clarification emphasizes a specific focus on drug-driven efficacy in the treatment of non-melanoma skin cancer. Dr. Babar Rao, acting as a Key Opinion Leader (KOL), confirmed that these outcomes are clinically meaningful and support the drug's viability as a non-surgical alternative. The treatment could potentially allow a majority of patients to avoid immediate surgical intervention and its associated risks. Analysts view this detailed guidance as a move to strengthen investor confidence in the company's lead product and its future prospects in the biotech market.